Lexicon Pharmaceuticals | LXRX - Trade Debtors


Lexicon Pharmaceuticals reported $2.38M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Abbott USD 11.22B 655M Mar/2026
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 23.48B 2.3B Jun/2026
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Illumina USD 764M 26M Jun/2026
Insmed USD 215.32M 36.77M Jun/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
J&J USD 22.54B 1.21B Mar/2026
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
MacroGenics USD 10.42M 2.95M Mar/2026
MannKind USD 43.21M 15.07M Jun/2026
Merck USD 12.21B 435M Mar/2026
Moderna USD 17M 54M Jun/2026
Novartis USD 9.85B 252M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Thermo Fisher Scientific USD 9.45B 247M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
United Therapeutics USD 310.3M 1.7M Jun/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024